Establishing the Validity of Brain Tumor Perfusion Imaging

建立脑肿瘤灌注成像的有效性

基本信息

项目摘要

ABSTRACT The principal goal of this competitive renewal is to establish clinical brain tumor perfusion imaging protocols strategically designed for high accuracy, physiologic sensitivity and clinical applicability. Dynamic susceptibility contrast (DSC) MRI is one of the most widely used advanced imaging techniques in neuro-oncology, with a reported use of 85% in all routine brain tumor scans at sites across the US and Europe. During the previous funding cycle, the singular aim of the project was to identify the most accurate DSC-MRI acquisition protocol(s) by developing, validating and applying a population-based digital reference object (DRO) and then verifying these protocols in patients with brain tumors. The most significant finding of this effort was the identification and clinical validation of an accurate single contrast agent dose and single-echo DSC-MRI protocol, which has now been adopted as the consensus recommendation by the brain tumor imaging community. Another key result of this project was the validation, using the DRO and a prospective patient study, of a single-dose, dual-echo DSC- MRI sequence, an approach that enables simultaneous assessment of DSC and dynamic contrast enhanced (DCE)-MRI data, as the protocol with highest accuracy, even across variable pulse sequence parameters and tissue properties. Building on the success of this prior work, we now aim to overcome two obstacles that still limit DSC-MRI’s clinical utility, accuracy, and multi-site consistency: i) a reliance on echo planar imaging (EPI) based pulse sequences that undermine the geometric fidelity, reliable colocalization of perfusion and anatomic images and accuracy of derived DCE-MRI data, and ii) lack of validation of, and a benchmark for, brain tumor DSC/DCE- MRI post-processing algorithms and software, for both single- and dual-echo acquisitions. These limitations represent critical and clinically relevant challenges that urgently need to be addressed. To address these issues, we propose to: 1) establish an anthropomorphic benchmark for validating brain tumor DSC DCE-MRI analysis tools and 2) develop a three-dimensional, dual-echo pulse sequence for simultaneous DSC/DCE MRI. In this project we will provide the neuro-oncology community with validated image acquisition and analysis methods for accurate, physiologic sensitive and clinically applicable DSC/DCE-MRI mapping methods in brain tumor patients. We will provide the first DSC/DCE-MRI anthropomorphic benchmark that can be used to validate existing and future algorithms and software, thereby improving multi-site and clinical trial consistency. Ultimately, validated DSC-MRI techniques will improve its reliability and relevancy across a range of clinical scenarios, including tumor localization, therapy response assessment, surgical and biopsy guidance, and multi-site clinical trials of conventional and targeted brain tumor therapies.
抽象的 这种竞争性更新的主要目标是建立临床脑肿瘤灌注成像方案 策略性设计,以高精度,生理敏感性和临床适用性。动态敏感性 对比度(DSC)MRI是神经肿瘤学中使用最广泛的高级成像技术之一, 据报道,在美国和欧洲的所有常规脑肿瘤扫描中使用85%。在上一个 资金周期,该项目的单一目的是确定最准确的DSC-MRI采集协议 通过开发,验证和应用基于人群的数字参考对象(DRO),然后验证 这些方案中的脑肿瘤患者。这项工作的最重要发现是识别和 精确的单对比剂剂量和单回波DSC-MRI方案的临床验证,该方案现已 被脑肿瘤成像社区通过作为共识建议。另一个关键结果 该项目是使用DRO和前瞻性患者研究的验证,是单剂量的双回声DSC- MRI序列,一种能够同时评估DSC和动态对比度增强的方法 (DCE)-MRI数据,作为具有最高精度的协议,即使在可变脉冲序列参数和 组织特性。在这项先前工作的成功基础上,我们现在旨在克服仍然限制的两个障碍 DSC-MRI的临床实用性,准确性和多站点一致性:i)依赖基于回声的平面成像(EPI) 破坏了几何忠诚度,可靠的灌注共定位和解剖图像的脉冲序列 并准确地衍生DCE-MRI数据,ii)缺乏对脑肿瘤DSC/DCE-的验证和基准 MRI后处理算法和软件,用于单回波采集。这些限制 代表迫切需要解决的关键和临床相关挑战。为了解决这些问题, 我们建议:1)建立一个拟人化基准,用于验证脑肿瘤DSC DCE-MRI分析 工具和2)为简单的DSC/DCE MRI开发了三维双回波脉冲序列。在这个 项目我们将为神经肿瘤学社区提供经过验证的图像获取和分析方法 精确,身体敏感且临床适用的DSC/DCE-MRI映射方法在脑肿瘤患者中。 我们将提供第一个DSC/DCE-MRI拟人化基准,可用于验证现有和 未来的算法和软件,从而提高了多站点和临床试验的一致性。最终,经过验证 DSC-MRI技术将在包括肿瘤在内的各种临床情况下提高其可靠性和相关性 定位,治疗反应评估,手术和活检指导以及多站点的临床试验 常规和靶向脑肿瘤疗法。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.
使用数字参考对象对多回波动态磁化率对比 MRI 进行系统评估。
  • DOI:
    10.1002/mrm.27914
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Stokes,AshleyM;Semmineh,NatenaelB;Nespodzany,Ashley;Bell,LauraC;Quarles,CChad
  • 通讯作者:
    Quarles,CChad
Imaging vascular and hemodynamic features of the brain using dynamic susceptibility contrast and dynamic contrast enhanced MRI.
  • DOI:
    10.1016/j.neuroimage.2018.04.069
  • 发表时间:
    2019-02-15
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Quarles CC;Bell LC;Stokes AM
  • 通讯作者:
    Stokes AM
Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object.
  • DOI:
    10.3174/ajnr.a5827
  • 发表时间:
    2018-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Semmineh NB;Bell LC;Stokes AM;Hu LS;Boxerman JL;Quarles CC
  • 通讯作者:
    Quarles CC
共 3 条
  • 1
前往

Christopher Chad Q...的其他基金

Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
弛豫对比成像作为 ALS 肌肉退化的生物标志物
  • 批准号:
    10783525
    10783525
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Imaging-based tumor forecasting to predict brain tumor progression and response to therapy
基于成像的肿瘤预测可预测脑肿瘤进展和治疗反应
  • 批准号:
    10706461
    10706461
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Imaging-based tumor forecasting to predict brain tumor progression and response to therapy
基于成像的肿瘤预测可预测脑肿瘤进展和治疗反应
  • 批准号:
    10367617
    10367617
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
弛豫对比成像作为 ALS 肌肉退化的生物标志物
  • 批准号:
    10357431
    10357431
  • 财政年份:
    2021
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer
多参数灌注 MRI 用于脑癌治疗反应评估
  • 批准号:
    9927886
    9927886
  • 财政年份:
    2020
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Establishing the validity of brain tumor perfusion imaging
建立脑肿瘤灌注成像的有效性
  • 批准号:
    9754786
    9754786
  • 财政年份:
    2017
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Establishing the validity of brain tumor perfusion imaging
建立脑肿瘤灌注成像的有效性
  • 批准号:
    10373105
    10373105
  • 财政年份:
    2017
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
  • 批准号:
    9182174
    9182174
  • 财政年份:
    2011
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
  • 批准号:
    8703037
    8703037
  • 财政年份:
    2011
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
  • 批准号:
    10062866
    10062866
  • 财政年份:
    2011
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Morphologic and Kinematic Adaptations of the Subtalar Joint after Ankle Fusion Surgery in Patients with Varus-type Ankle Osteoarthritis
内翻型踝骨关节炎患者踝关节融合手术后距下关节的形态和运动学适应
  • 批准号:
    10725811
    10725811
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Alpha-emitter Imaging for Dosimetry and Treatment Planning
用于剂量测定和治疗计划的阿尔法发射体成像
  • 批准号:
    10713710
    10713710
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits
用于神经微电路多模态分析的高密度碳纤维电极阵列的商业转化
  • 批准号:
    10761217
    10761217
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别:
Engineering Human Organizer To Study Left-Right Symmetry Breaking
工程人类组织者研究左右对称性破缺
  • 批准号:
    10667938
    10667938
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
    $ 36.99万
  • 项目类别: